When should ampicillin‑sulbactam (Unasyn) be used instead of colistin (polymyxin E) for antibacterial coverage, and what are the differences in their antimicrobial spectra and dosing?

Ampicillin-Sulbactam vs Colistin: Antimicrobial Coverage and Clinical Use

Ampicillin-sulbactam (Unasyn) should be used instead of colistin for community-acquired infections caused by susceptible organisms and for carbapenem-resistant Acinetobacter baumannii (CRAB) infections when the organism is susceptible to sulbactam (MIC ≤4 mg/L), while colistin is reserved for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) and multidrug-resistant gram-negative infections when other options are unavailable.

Antimicrobial Spectrum Differences

Ampicillin-Sulbactam Coverage

Ampicillin-sulbactam combines a beta-lactam with a beta-lactamase inhibitor that has intrinsic activity against Acinetobacter species 1. The FDA-approved indications include:

• Beta-lactamase producing organisms: Staphylococcus aureus, E. coli, Klebsiella spp., Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus 1
• Infection sites: Skin/soft tissue, intra-abdominal, and gynecological infections 1
• Critical limitation: High resistance rates among community-acquired E. coli make it unsuitable for empiric community-acquired intra-abdominal infections 2

Colistin Coverage

Colistin (polymyxin E) has activity against carbapenem-resistant, non-fermenting gram-negative bacilli, particularly:

• Primary targets: Carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), and some carbapenem-resistant Enterobacterales 3
• No activity: Gram-positive organisms, anaerobes, or Proteus species

Clinical Decision Algorithm

When to Use Ampicillin-Sulbactam

1. Community-Acquired Infections (Mild-to-Moderate Severity)

• Use for mixed aerobic-anaerobic infections when local E. coli resistance is <20% 2
• Do not use as empiric therapy due to high E. coli resistance rates in most settings 2

2. Carbapenem-Resistant Acinetobacter baumannii (CRAB) This is where ampicillin-sulbactam demonstrates clear superiority over colistin:

• Preferred when sulbactam MIC ≤4 mg/L 4

• Recent high-quality evidence shows ampicillin-sulbactam-based therapy achieves:

  • Lower 28-day mortality: 20% vs 61% with colistin (adjusted RR 0.16) 5
  • Higher clinical success: 55% vs 32% at 28 days 5
  • Reduced nephrotoxicity: 13% vs 38% 6
  • Better microbiological eradication: 61.5% vs lower rates with colistin 7, 8

• Dosing for CRAB:

  • High-dose sulbactam 6-9 g/day in divided doses 4, 6
  • Optimal appears to be 9 g every 8 hours (total 27-36 g/day) 5, 9
  • Consider combination with tigecycline or polymyxins for severe infections 6, 10

When to Use Colistin

1. Difficult-to-Treat Resistant Pseudomonas aeruginosa (DTR-PA)

• Recommended for DTR-PA infections when organism is susceptible 3
• Survival rates 39-83% in retrospective studies 3

2. Carbapenem-Resistant Gram-Negative Infections

• Use when newer beta-lactam/beta-lactamase inhibitors unavailable or organism resistant 3
• Reserve as last-line therapy due to nephrotoxicity concerns 3, 4

3. Critical Dosing Requirements

• Loading dose: 9 million units (MU) or 5 mg/kg 3, 4
• Maintenance: 4.5 MU twice daily, adjusted by formula: 2.5 mg × (1.5 × CrCl + 30) 3
• Loading dose mandatory—steady state takes 2-3 days without it 4

Key Safety Considerations

Ampicillin-Sulbactam

• Nephrotoxicity: 15.3% vs 33% with colistin 7
• Generally well-tolerated at high doses 5, 9
• Adjust for renal dysfunction 1

Colistin

• Acute kidney injury is the major limiting toxicity 3
  • Occurs in 33-42% of patients 7, 8
  • Associated with clinical failure and mortality 3
  • Mandatory renal function monitoring during therapy 3
• Suboptimal lung penetration—may be undetectable in BAL fluid 4
• Elderly and chronic kidney disease patients at highest risk 3

Critical Clinical Pitfalls

1. Do not use ampicillin-sulbactam empirically for community-acquired E. coli infections—resistance rates too high 2

2. Do not use standard colistin doses without a loading dose—leads to 2-3 days of subtherapeutic levels 4

3. For CRAB pneumonia, ampicillin-sulbactam is superior to colistin monotherapy based on the most recent 2025 evidence 5—this represents a paradigm shift from older practices

4. Combination therapy considerations:

   • For CRAB: Sulbactam + polymyxins shows best outcomes 10
   • For colistin: Combination therapy benefit remains controversial 3
   • Network meta-analysis shows colistin + carbapenem (COL_CAR) has best mortality outcomes (SUCRA 83.6) 3

5. Therapeutic drug monitoring: Not routinely available for colistin despite highly variable pharmacokinetics in critically ill patients 11

Specific Recommendations by Infection Type

Ventilator-Associated Pneumonia (CRAB)

• First-line: High-dose ampicillin-sulbactam (9g q8h) ± tigecycline or polymyxin 5, 8
• Colistin reserved for sulbactam-resistant strains or contraindications

Bloodstream Infections (CRAB)

• Cefoperazone-sulbactam shows 28-day mortality of 29.3% vs 51.9% with tigecycline 6
• Combination with carbapenem improves outcomes 6

DTR-PA Infections

• Colistin-based therapy recommended (weak recommendation) 3
• Consider newer agents (ceftazidime-avibactam, ceftolozane-tazobactam) first if available 3

3, 2, 4, 6, 1, 5, 7, 8, 10